心力衰竭患者经卡维地络治疗后血脑钠肽前体N末端的变化
Change of N-terminal pro B-type natriuretic peptide levels in systolic heart failure after treatment with carvedilol
摘要
目的：观察心力衰竭患者经卡维地络治疗后B型钠尿肽前体N末端（NT-proBNP）的变化，探讨血NT-proBNP水平监测心衰药物治疗效果的可行性。方法：30例NYHA心功能Ⅱ～Ⅳ级收缩性心衰患者，随机给予标准治疗（标准治疗组，n=15）或“标准＋卡维地络”治疗（卡维地络组，n=15），观察治疗前后心功能和血NT-proBNP水平的变化，并与健康人（n=22）血NT-proBNP进行比较。结果：心力衰竭患者血NT-proBNP为（1919．0±1565．7）pg／ml，显著高于健康人群E（37．1±19．7）pg／ml，P〈0．003。卡维地络组和标准治疗组治疗前的一般情况具有可比性；治疗后卡维地络组血NT-proBNP（pg／m1）明显下降（1732±1404vs1134±708，P〈0．01），而标准治疗组治疗前后无显著差异（2105±1727vs1905±1509，P〉0．05）。结论：收缩性心衰患者经卡维地络治疗后血NT-proBNP水平下降明显，血NT-proBNP水平可能有助于监测心衰药物治疗效果。
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2006年第8期922-923,共2页
Academic Journal of Second Military Medical University
参考文献10
-
1Talwar S,Siebenhofer A,Williams B,et al.Influence of hypertension,left ventricular hypertrophy,and left ventricular systolic dysfunction on plasma N terminal proBNP[J].Heart,2000,83:278-282.
-
2Hammerer-Lercher A,Neubauer E,Muller S,et al.Head-to-head comparison of N-terminal pro-brain natriuretic peptide,brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction[J].Clin Chim Acta,2001,310:193-197.
-
3Luchner A,Hengstenberg C,Lowel H,et al.N-terminal pro-brain natriuretic peptide after myocardial infarction:a marker of cardio-renal function[J].Hypertension,2002,39:99-104.
-
4Maisel AS,McCord J,Nowak RM,et al.Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction.Results from the Breathing Not Properly Multinational Study[J].J Am Coll Cardiol,2003,41:2010-2017.
-
5Lubien E,DeMaria A,Krishnaswamy P,et al.Utility of B-natriuretic peptide in detecting diastolic dysfunction:comparison with Doppler velocity recordings[J].Circulation,2002,105:595-601.
-
6Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:Executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure):Developed in collaboration with the international society for heart and lung transplantation; endorsed by the heart failure society of america[J].Circulation,2001,104:2996-3007.
-
7Latini R,Masson S,Anand I,et al.Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure:the Valsartan Heart Failure Trial (Val-HeFT)[J].Circulation,2002,106:2454-2458.
-
8Troughton RW,Frampton CM,Yandle TG,et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations[J].Lancet,2000,355:1126-1130.
-
9Frantz RP,Olson LJ,Grill D,et al.Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure[J].Am Heart J,2005,149:541-547.
-
10汪芳,顼志敏,王莉,边文彦,贾宣,段兵,李卫,李一石.慢性心力衰竭患者血浆激素水平动态变化及其临床意义[J].中华内科杂志,2005,44(7):490-494. 被引量：4
二级参考文献12
-
1Francis GS, Benedict C, Johnstone DE,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation, 1990,82:1724-1729.
-
2Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation,1990,82:1730-1736.
-
3Swedberg K, Eneroth P, Kjekshus J, et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol, 1990,66:40D-44D .
-
4Wieczorek SJ, Wu AH, Christenson R, et al.A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J,2002,144:834-839.
-
5Maisel A.B-type natriuretic peptide levels: diagnostic and therapeutic potential. Cardiovasc Toxicol, 2001,1:159-64.
-
6Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta,2001,310:193-197.
-
7Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003,338:107-115.
-
8Groenning BA, Nilsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail,2001,3:699-708.
-
9Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol, 1994,24:583-591.
-
10Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol, 1994,24:583-591.
共引文献3
-
1张春治,田晖,刘政国.卡维地洛的药理学特性和临床治疗意义[J].医用放射技术杂志,2006(4):5-7.
-
2覃泱,徐彤彤,吕祥威.慢性心力衰竭患者血清瘦素和脂联素水平变化及意义研究[J].中国全科医学,2013,16(33):3909-3912. 被引量：15
-
3邹筱冬,崔进,何芸.慢性心力衰竭患者血清脑钠肽、瘦素和脂联素水平变化及意义[J].山东医药,2016,56(17):59-61. 被引量：15
